SOURCE: Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP

November 01, 2014 09:30 ET

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in iBio, Inc. (IBIO) to Contact the Firm

NEW YORK, NY--(Marketwired - November 01, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in iBio, Inc. ("iBio" or the "Company") (NYSE: IBIO) of the December 23, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against iBio and the Company's CEO.

A complaint has been filed in the United States District Court for the District of Delaware on behalf of all persons who purchased iBio common stock between October 13, 2014 and October 23, 2014 (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that during the Class Period, iBio issued false and misleading statements by incorrectly suggesting that the Company's Launch platform patents and related proprietary technology would be licensed by a potential manufacturer of ZMapp, an experimental Ebola drug.

On October 23, 2014, an article published on www.SeekingAlpha.com alleged that iBio's representations regarding its involvement in the emergency response to the Ebola virus outbreak were materially false and misleading.

Following this news, the price of the Company's stock declined by $0.14 per share, or over 7%, to close on October 23, 2014 at $1.63 per share.

Request more information now by clicking here: www.faruqilaw.com/IBIO. There is no cost or obligation to you.

Take Action

If you invested in iBio common stock or options between October 13, 2014 and October 23, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/IBIO. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding iBio's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    rgonnello@faruqilaw.com
    Telephone: (877) 247-4292 or (212) 983-9330